# CJC-1295 and Sermorelin FAQ — AJW Peptides

> Frequently asked questions about CJC-1295 and sermorelin — two GHRH-analog research peptides — answered directly from the peer-reviewed literature, with citations.

Direct answers to the questions researchers and readers most often bring to CJC-1295, sermorelin, and the growth hormone axis.

## What is CJC-1295?

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). It is built on the first 29 amino acids of natural GHRH, with four chemical substitutions that prevent enzymatic breakdown. In its 'DAC' variant, it also carries a handle that binds it to the blood protein albumin, extending its active life in circulation to roughly 5-8 days. It is a research chemical — not approved for human use by the FDA or any major regulator, not recommended for 503A compounding, and sold for laboratory research only [1][4].

## What does CJC-1295 do?

CJC-1295 binds the GHRH receptor on the anterior pituitary and stimulates pulsatile release of the body's own growth hormone (GH). GH in turn raises IGF-1 in the liver and peripheral tissues. In published human pharmacology studies, single subcutaneous doses produced dose-dependent 2- to 10-fold increases in mean plasma GH sustained for 6 or more days, and 1.5- to 3-fold increases in IGF-1 sustained for 9-11 days [4]. Pulsatile GH secretion was preserved even under continuous CJC-1295 stimulation [5]. This desk does not advise on use.

## Is CJC-1295 safe?

The honest answer is that the published safety record is thin and short-term. Human evidence is limited to early pharmacology studies; there are no large or long-term safety trials. The FDA reviewed CJC-1295 at the 2024 Pharmacy Compounding Advisory Committee and did not recommend it for 503A compounding, citing immunogenicity and other safety concerns [1]. Known mechanism-based concerns include sustained IGF-1 elevation (associated with cancer risk in epidemiologic data), fluid retention from GH-driven sodium retention, effects on insulin sensitivity, and the historical discontinued development program [4][7]. This site gives no medical advice.

## How much CJC-1295 should I take?

This desk does not provide dosing recommendations for any compound. The published human studies used specific doses under controlled research conditions — for example, 30 or 60 mcg/kg subcutaneously in healthy adults [4] — but reporting those study conditions is not a recommendation to replicate them. CJC-1295 is not approved for human use, has no established safe therapeutic dose for any adult indication, and the community dosing protocols circulating online are not derived from controlled trials. Nothing on this page constitutes medical or dosing advice.

## What is sermorelin?

Sermorelin is the natural N-terminal 1-29 fragment of human growth-hormone-releasing hormone (GHRH) — the shortest sequence that retains full activity at the GHRH receptor. It was previously FDA-approved for pediatric GH deficiency and withdrawn from the US market in 2008 for commercial reasons, not safety or efficacy issues. Today it is available through compounding pharmacies as a Category 1 bulk substance under FDA's 503A policy [10]. It stimulates the pituitary to release the body's own GH in a pulsatile, feedback-regulated pattern [1].

## What does sermorelin do to the body?

Sermorelin binds the GHRH receptor on pituitary somatotroph cells and activates adenylate cyclase signaling, stimulating GH synthesis and release. Because it acts via the pituitary's own machinery, physiologic feedback — somatostatin inhibition and IGF-1 negative feedback — remains intact, preserving the body's natural pulsatile GH rhythm [1][10]. GH then drives IGF-1 production, which mediates downstream anabolic and metabolic effects. In a multicenter pediatric trial, once-daily subcutaneous sermorelin raised first-year height velocity from roughly 4.1 cm/year to 7-8 cm/year in GH-deficient children, without excessive IGF-1 generation [11].

## Does sermorelin work?

It depends on what 'work' means. For its approved pediatric indication, yes — there is a multicenter trial showing accelerated linear growth in GH-deficient children [11]. For the adult anti-aging and body-composition uses widely marketed today, the evidence is far weaker. A 2008 *Annals of Internal Medicine* editorial concluded that using GH secretagogues to prevent or treat aging is 'not yet ready for prime time' [9]. A GHRH-analog adult RCT (using a related compound) showed favorable cognitive effects and body-fat reduction [8], but that is a single trial with a related compound, not sermorelin itself. Absent large, long-term trials, strong efficacy claims in healthy adults are not supported by the literature.

## How long does it take for sermorelin to work?

Research-use and telehealth communities consistently describe sermorelin as a slow compound — a 'slow burn' rather than a rapid change. People commonly report that the first four to eight weeks feel uneventful, with sleep improvements appearing earliest (often within two weeks), and changes in body composition and energy taking two to three months of consistent nightly use to become noticeable, if they appear at all. Community consensus strongly emphasizes daily consistency and patience. These are anecdotal accounts, not clinical timelines — no controlled trial has established a specific onset timeline for adult wellness outcomes.

## What is the difference between CJC-1295 DAC and no-DAC (Modified GRF 1-29)?

The DAC (Drug Affinity Complex) variant of CJC-1295 carries a maleimidopropionyl linker that forms a covalent bond with serum albumin, extending its plasma half-life to approximately 5-8 days. The no-DAC variant — often sold as Modified GRF 1-29 or Mod GRF 1-29 — has the same four amino-acid substitutions but lacks the albumin-binding handle, so it is cleared within hours [7][4]. The two forms behave very differently in practice: the DAC form sustains GH and IGF-1 elevation for days from a single dose, which drives more pronounced fluid retention, glucose-sparing, and prolonged IGF-1 exposure. They are routinely conflated in community and commercial contexts, which is a real safety concern.

## Is sermorelin the same as CJC-1295?

No. They are related but distinct compounds. Sermorelin is the bare natural 1-29 N-terminal fragment of GHRH, without modification. CJC-1295 is an engineered analog built on that same 1-29 scaffold, with four amino-acid substitutions for protease resistance and (in the DAC form) an albumin-binding handle [7]. Sermorelin has a prior FDA approval and 503A Category 1 status; CJC-1295 has neither and was not recommended for 503A compounding at the 2024 Pharmacy Compounding Advisory Committee [1][10]. Their half-lives differ by a factor of roughly 20 to 50 depending on form. See the [comparison page](/compare) for a full side-by-side.

## Are CJC-1295 and sermorelin banned in sport?

Yes, both are prohibited in sport. CJC-1295 is banned at all times under WADA Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), and it is detectable by established LC-MS/MS methods — including from seized samples [2]. Sermorelin and GHRH analogs more broadly are prohibited in competitive sport under the WADA Prohibited List's hormone and metabolic modulator category. Any tested athlete who uses either compound risks an anti-doping violation.

## What is the GH/IGF-1 axis?

The GH/IGF-1 axis is the hormonal cascade that regulates growth hormone secretion and its downstream effects. The hypothalamus releases GHRH, which tells the anterior pituitary to release GH in pulses. GH then acts on the liver and peripheral tissues to generate IGF-1 (insulin-like growth factor 1), which mediates many of GH's downstream effects on cell growth, metabolism, and tissue repair. Somatostatin, released by the hypothalamus, acts as the brake on GH release. Both CJC-1295 and sermorelin act at the first step of this cascade — at the GHRH receptor — to stimulate the axis from the top [1].

---

An independent literature digest on GHRH-analog research peptides — citations, not prescriptions.